Latest Obsessive–compulsive disorder Stories
A new study by researchers at Columbia University Mailman School of Public Health's Center for Infection and Immunity indicates that pediatric obsessive-compulsive disorder (OCD)
This week marks the Obsessive Compulsive Foundation's annual weekend conference, an event where speakers and seminars offer support to those living with OCD
New research shows that childhood adversity is associated with diminished neural activity in brain regions implicated in the anticipation of possible rewards.
On Tuesday, Medtronic Inc said that it received regulatory approval in Europe for an implantable brain simulator to treat patients that suffer from obsessive-compulsive disorder.
TOLOCHENAZ, Switzerland, July 14 /PRNewswire-FirstCall/ -- - CE Mark Approval for Medtronic's Reclaim(R) DBS Therapy for Treatment of Chronic, Severe Obsessive-Compulsive Disorder Medtronic today announced that Reclaim(R) Deep Brain Stimulation (DBS) Therapy has received CE (Conformite Europeene) Mark approval for the treatment of chronic, severe treatment-resistant obsessive-compulsive disorder (OCD).* This is the first time that a deep brain stimulation therapy has gained approval...
Pioneering therapeutic trials to investigate the effectiveness of deep brain stimulation (DBS) in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the world
For a child with obsessive-compulsive disorder, soothing anxiety or helping with OCD behaviors could lead to more severe symptoms, U.S. researchers said.
A new multi-center study, conducted at The Feinstein Institute for Medical Research in collaboration with five other centers throughout the country, tested the commonly prescribed antidepressant citalopram and found that it was no more effective than placebo in altering obsessive features of the condition â€“ the spinning, rocking and repetitive behavior.
Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes.
Citalopram (Celexa), a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to a multi-site clinical trial guided by lead author Bryan H. King